Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Area of Science:

• Immunology
• Oncology
• Cancer Therapy

Background:

• Immune checkpoint inhibitors (ICI) activate anti-tumor immunity but have limited response rates and frequent resistance in advanced cancers.
• Predictive biomarkers like PD-L1 expression and mismatch-repair deficiency are used, but resistance to ICI monotherapy persists.
• Anti-angiogenesis therapy, known for pruning tumor vasculature, also reprograms the tumor immune microenvironment.

Purpose of the Study:

• To review the latest understanding of combining ICI with anti-angiogenesis therapy for cancer treatment.
• To highlight advances and promising outcomes from clinical trials investigating this combination therapy.

Main Methods:

• Review of preclinical studies demonstrating the synergistic effects of combining ICI and anti-angiogenesis therapy.
• Analysis of clinical trial data investigating the efficacy and outcomes of this combination in cancer patients.
• Examination of how anti-angiogenesis therapy reprograms the tumor immune microenvironment to enhance ICI efficacy.

Main Results:

• Preclinical studies show combination therapy is superior to monotherapy, increasing anti-tumor immune cells and reducing immune checkpoints.
• Clinical trials investigating ICI combined with anti-angiogenesis treatment have yielded promising outcomes.
• Combination therapy demonstrates potential to overcome resistance to ICI monotherapy.

Conclusions:

• Combining immune checkpoint inhibitors with anti-angiogenesis therapy represents a promising strategy to improve cancer treatment response rates.
• This combination therapy effectively reprograms the tumor immune microenvironment, enhancing anti-tumor immune responses.
• Further clinical investigation and application of this synergistic approach are warranted for advanced cancer patients.